Detalles de la búsqueda
1.
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
J Sex Med
; 13(12): 1930-1937, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27692842
2.
Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis.
J Bone Miner Metab
; 33(1): 61-72, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24714934
3.
Assessment of ospemifene or lubricants on clinical signs of VVA.
J Sex Med
; 11(4): 1033-1041, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24443923
4.
Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.
Menopause
; 29(3): 304-308, 2022 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35213517
5.
Response and Rebuttal to Editorial Comment on TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women with Vulvar and Vaginal Atrophy: The REJOICE Trial.
J Sex Med
; 13(12): 1940-1941, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27914565
6.
Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use.
Eur J Contracept Reprod Health Care
; 16(2): 85-94, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21417560
7.
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
BMC Musculoskelet Disord
; 11: 130, 2010 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-20569451
8.
Systemic estradiol levels with low-dose vaginal estrogens.
Menopause
; 27(3): 361-370, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31794498
9.
17ß-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Menopause
; 27(12): 1382-1387, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32740481
10.
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Menopause
; 27(11): 1236-1241, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33110039
11.
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Am J Obstet Gynecol
; 200(2): 172.e1-10, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19110224
12.
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Am J Obstet Gynecol
; 200(3): 238.e1-238.e10, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19167693
13.
Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.
J Womens Health (Larchmt)
; 28(2): 237-243, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30484734
14.
Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review.
Menopause
; 26(7): 800-807, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30889085
15.
Early onset of action with a 17ß-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Menopause
; 26(11): 1259-1264, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31688572
16.
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Menopause
; 26(5): 513-519, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30516713
17.
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17ß-estradiol/progesterone.
Menopause
; 26(6): 637-642, 2019 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30601452
18.
Pharmacokinetics and Tolerability of a Novel 17ß-Estradiol and Progesterone Intravaginal Ring in Sheep.
J Pharm Sci
; 108(8): 2677-2684, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30959058
19.
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Menopause
; 26(7): 720-727, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30694918
20.
Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep.
Drug Deliv Transl Res
; 9(5): 1008-1016, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31066007